Gilead Sciences Inc at Nasdaq Investor Conference Transcript

Dec 07, 2022 / 01:00PM GMT
Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director

All right. Perfect. Thanks for joining us for the next session. I'm Matthew Harrison, one of the biotech analysts at Morgan Stanley. Really pleased to have Dan O'Day, the Chairman and CEO at Gilead with us.

Just a reminder, personal analyst holding disclosures are available on morganstanley.com/researchdisclosures. And with that fun out of the way, Dan, thanks for being here. I thought maybe a good place to start off is we're sort of -- I guess you're 3 years into your tenure almost?

Daniel P. O'Day - Gilead Sciences, Inc. - Chairman & CEO

Yes. Almost 4.

Questions and Answers:

Matthew Kelsey Harrison - Morgan Stanley, Research Division - Executive Director

Almost 4, yes, that's right. And obviously, part of the -- when you came in, right, was a transformation of the company, right? You put a lot of capital to work on external assets. So where do you think you are in the transition of the company, sort
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot